Evidence map›Paper›PMID 34100536›Full record

ArticleJournal of analytical toxicology2021

Identification of Gamma-Butyrolactone in JUUL Liquids.

Alaina K Holt, Justin L Poklis, Caroline O Cobb, Michelle R Peace

Open access · greenAbstract readCase Reports
In one paragraph

Article in Journal of analytical toxicology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Design of CScientific reports · 2025
    Article
  2. Article
  3. Ethyl acetate in e-liquids: Implications for breath testing.Journal of analytical toxicology · 2024
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Alaina K HoltDepartment of Forensic Science, Virginia Commonwealth University, 1015 Floyd Avenue, Room 2015, Richmond, VA 23284, USA.ORCID 0000-0002-0474-6622
Justin L PoklisDepartment of Pharmacology & Toxicology, Virginia Commonwealth University, PO Box 980613, Richmond, VA 23298-0613, USA.ORCID 0000-0001-5470-5717
Caroline O CobbDepartment of Psychology, Virginia Commonwealth University, 808 West Franklin St, Richmond, VA 23298, USA.ORCID 0000-0003-3258-252X
Michelle R PeaceDepartment of Forensic Science, Virginia Commonwealth University, 1015 Floyd Avenue, Room 2015, Richmond, VA 23284, USA.
Virginia Commonwealth University · US

Funding

Project 4: Using a prospective cohort survey to test population-level predictions generated by Projects 1-3U54DA036105 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI BRELAND, ALISON, EISSENBERG, THOMAS EVAN · 2018 to 2022
$20.8M
VCU Center for Drug Addiction ResearchP30DA033934 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI Matthew Sean Halquist · 2014 to 2026
$13.8M
National Institute of Justice 2018-75-CX-0036NIDA NIH HHS P30 DA033934NIDA NIH HHS U54 DA036105NIDA NIH HHS U54DA036105
6 · The paper itself

Abstract

Gamma-butyrolactone (GBL), a commonly used industrial solvent, is used recreationally as a central nervous system (CNS) depressant and, therefore, is a United States Drug Enforcement Agency List 1 chemical of the Controlled Substances Act. GBL was identified presumptively in the liquid from JUUL Virginia Tobacco flavored pods during routine untargeted screening analysis of e-cigarette products by gas chromatography-mass spectrometry (GC-MS). Methods for the analysis of GBL were developed for GC-MS and liquid chromatography-tandem mass spectrometry (LC-MS-MS) in the liquids and the aerosol generated from the liquid. Three flavors of JUUL pods available at the time of analysis were obtained by direct purchase from the manufacturer, purchase from a local vape shop and submission from a third party. The only liquid flavor to contain GBL was Virginia Tobacco, with an average of 0.37 mg/mL of GBL, and it was detected in the aerosol. Studies evaluating the pharmacological effects of inhaling GBL do not exist; however, a case report of chronic oral GBL ingestion indicates acute lung injury. The identification of GBL in an e-cigarette product purportedly compliant with federal regulation continues to demonstrate public health and public safety concerns.

Indexed as

Electronic Nicotine Delivery SystemsVaping4-ButyrolactoneChromatography, LiquidGas Chromatography-Mass SpectrometryHumansUnited States4-Butyrolactone

Identifiers

PMID34100536
PMCPMC8446641
OpenAlexW3172405687

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.